Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
Deh3tvfBVrsjydjT
